trending Market Intelligence /marketintelligence/en/news-insights/trending/ghggcfplbkmmbj6r1i-7ya2 content esgSubNav
In This List

MabVax regains compliance with Nasdaq's minimum bid price rule

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


MabVax regains compliance with Nasdaq's minimum bid price rule

MabVax Therapeutics Holdings Inc. regained compliance with the Nasdaq Capital Market's minimum bid price requirement.

The closing bid price of MabVax common stock had been at $1 per share or more for at least 10 days before the March 5 deadline for continued listing.

The San Diego-based company was able to maintain the minimum price as a result of its 1-to-3 reverse stock split.

The biotechnology company, developing treatments for cancer, previously regained compliance with Nasdaq's minimum equity requirement after raising $4.8 million during the third quarter of 2017.